GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
== Further reading == Economy, Elizabeth C. (2018). The Third Revolution: Xi Jinping and the New Chinese State. Oxford University Press. ISBN 978-0-19-086607-5. Goodman, David S. G. (2015). Handbook of the Politics of China. Edward Elga. ISBN 978-1-78254-437-1. Li, Cheng (2014a). "Xi Jinping's Inner Circle (Part 2: Friends from Xi's Formative Years)" (PDF). Hoover Institution. Archived (PDF) from the original on 26 September 2020. Retrieved 15 July 2020. Simon, Denis Fred; Cong, Cao (2009). China's Emerging Technological Edge: Assessing the Role of High-End Talent. Cambridge University Press. ISBN 978-0-521-88513-3. Yang, Rufeng (2014). 習近平如何改變中國 [How Xi Jinping is changing China]. China Interpretation Series (in Chinese). Bonfire Limited. p. 12. ISBN 978-986-5721-05-3. Retrieved 23 August 2024. Zhu, Pengpeng (2007). 谜一样的人生 [A Mysterious Life] (in Chinese). Tianma Publishing. ISBN 978-0-9787999-2-2. Retrieved 23 August 2024.
These findings highlight the significance of TANGO1 in building and ER exit site, controlling the quantities and quality of cargo exported, which is necessary for life.Membrane permeant peptides of TANGO1 affect hyper collagen secretion in normal and cells of patients with scleroderma, and in a zebra fish model of wound healing. These findings raise the possibility of targeting TANGO1 to control skin scarring, wound healing and fibrosis.
A series of WHO yaws control efforts, which began shortly after the creation of the WHO in 1948, succeeded in eradicating the disease locally from many countries, but have not lasted long enough to eradicate it globally. The Global Control of Treponematoses (TCP) programme by the WHO and the UNICEF was launched in 1952 and continued until 1964. A 1953 questionnaire-based estimate was that there were 50–150 million yaws cases in 90 countries. The global prevalence of yaws and the other endemic treponematoses, bejel and pinta, was reduced by the Global Control of Treponematoses (TCP) programme between 1952 and 1964 from about 50 million cases to about 2.5 million (a 95% reduction). However, "premature integration of yaws and other endemic treponematoses activities into weak primary health-care systems, and the dismantling of the vertical eradication programmes after 1964, led to the failure to finish with the remaining 5% of cases" and also led to a resurgence of yaws in the 1970s, with the largest number of case found in the Western Africa region. Following the cessation of this program, resources, attention and commitment for yaws gradually disappeared, and yaws remained at a low prevalence in parts of Asia, Africa, and the Americas with sporadic outbreaks. With few cases, mainly affecting poor, remote communities with little access to treatment, yaws became poorly known, yaws knowledge and skills died out even among health professionals, and yaws eradication was not seen as a high priority.
== Structure == The R1 plasmid belongs to the IncFII plasmid group. The Inc plasmid group stands for incompatibility, and plasmids are classified into this group when two plasmids can't steadily propagate in the same host. The major incompatibility group involved in resistance and virulence gene transfer is the IncF group. Since R1 is an IncFII plasmid, that means it carries the FII replicon. This plasmid subtype often carries blaCTX-M genes.
Sources: en.wikipedia.org
These readers typically use optical and/or computer vision techniques to evaluate the contents of the microtiter plate wells. One of the first applications of robotics in biology was peptide and oligonucleotide synthesis. One early example is the polymerase chain reaction (PCR) which is able to amplify DNA strands using a thermal cycler to micromanage DNA synthesis by adjusting temperature using a pre-made computer program. Since then, automated synthesis has been applied to organic chemistry and expanded into three categories: reaction-block systems, robot-arm systems, and non-robotic fluidic systems. The primary objective of any automated workbench is high-throughput processes and cost reduction. This allows a synthetic laboratory to operate with a fewer number of people working more efficiently.
== Preparation == Balbacua has numerous variations when it comes to the spices and secondary ingredients used. A common aspect of the dish, however, is the use of collagen-rich parts of beef, including oxtail, skin, knuckles, and other cartilaginous beef cuts in addition to regular beef cuts. These are cooked for around four to six hours until the meat is falling off the bones and is very tender. The collagen from the skin and cartilage thickens the soup into a gelatinous consistency. Common spices used include garlic, onion, black or white pepper, labuyo chilis, ginger or turmeric, annatto (achuete) oil, star anise (sangke), fermented black beans (tausi), bay leaves, coconut vinegar (sukang tuba), lemongrass (tanglad), fish sauce (patis), leeks or scallions, soy sauce or salt, calamansi, and so on. Secondary ingredients are similarly variable, including pechay, ground peanuts, baked beans, tomatoes, and saba bananas. Based on the ingredients, balbacua has sometimes been described as being a cross between puchero and kare-kare dishes. Balbacua is typically served with white rice or with misua or miki noodles (the latter variants are differentiated as balbacua con misua and balbacua con miki, respectively).
== Diagnosis == VWD is diagnosed by a combination of a personal or family history of excessive bleeding plus lab tests showing abnormalities in either the amount or function of vWF or factor VIII. Basic tests performed in any patient with bleeding problems are a complete blood count, activated partial thromboplastin time (aPTT), prothrombin time with an International Normalized Ratio, thrombin time, and fibrinogen level. People with abnormal tests typically undergo further testing for hemophilias. Other coagulation factor assays may be performed depending on the results of a coagulation screen. People with von Willebrand disease typically display a normal prothrombin time and a variable prolongation of aPTT, depending on whether sufficient VWF is available to perform its carrier function for factor VIII. When VWD is suspected, blood plasma of a patient must be investigated for quantitative and qualitative deficiencies of VWF. This is achieved by measuring the amount of VWF in a VWF antigen assay and the functionality of VWF with a glycoprotein (GP)Ib binding assay, VWF antibody assay, or a ristocetin cofactor activity (RiCof) assay. Factor VIII levels are also performed because factor VIII is bound to VWF which protects the factor VIII from rapid breakdown within the blood. Deficiency of VWF can then lead to a reduction in factor VIII levels, which explains the elevation in PTT.
The use of old technologies plays a large factor in how hazardous wastewater results in contaminating the environment. This is especially prominent in small and medium-sized tanneries in developing countries. The UN Leather Working Group (LWG) "provides an environmental audit protocol, designed to assess the facilities of leather manufacturers," for "traceability, energy conservation, [and] responsible management of waste products."
=== Wound cleansing === Dirt or dust on the surface of the wound, bacteria, tissue that has died, and fluid from the wound may be cleaned. The evidence supporting the most effective technique is not clear and there is insufficient evidence to conclude whether cleaning wounds is beneficial for promoting healing or whether wound cleaning solutions (polyhexamethylene biguanide, aqueous hydrogen peroxide, etc.) are better than sterile water or saline solutions to help venous leg ulcers heal. It is uncertain whether the choice of cleaning solution or method of application makes any difference to venous leg ulcer healing.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.